CHAPTER 1:INTRODUCTION
1.1.Report description
1.1.Key benefits for stakeholders
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models
1.3.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies, 2019
3.3.Top player positioning, 2019
3.4.Porter's five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Sedentary and unhealthy lifestyle
3.5.1.2.Increased availability of continuous glucose monitoring
3.5.1.3.Increasing investment in research and development (R&D) for human recombinant insulin
3.5.1.4.Increase in government expenditure on healthcare
3.5.2.Restraints
3.5.2.1.Adverse effects associated with the use of rapid acting insulin
3.5.3.Opportunities
3.5.3.1.Untapped opportunities and undiagnosed population in developing regions
3.5.4.Impact analysis
3.6.COVID-19 Impact Analysis On Rapid Acting Insulin Market

CHAPTER 4:RAPID ACTING INSULIN MARKET, BY PRODUCT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Lispro Insulin
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Aspart Insulin
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Glulisine Insulin
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

CHAPTER 5:RAPID ACTING INSULIN MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Type 1 Diabetes
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Type 2 Diabetes
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

CHAPTER 6:RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital Pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Drug Stores & retail pharmacies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Online providers
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:RAPID ACTING INSULIN MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America rapid acting insulin market, by country
7.2.2.1.U.S.
7.2.2.1.1.Market size and forecast, by product
7.2.2.1.2.Market size and forecast, by indication
7.2.2.1.3.Market size and forecast, by distribution channel
7.2.2.2.Canada
7.2.2.2.1.Market size and forecast, by product
7.2.2.2.2.Market size and forecast, by indication
7.2.2.2.3.Market size and forecast, by distribution channel
7.2.2.3.Mexico
7.2.2.3.1.Market size and forecast, by type
7.2.2.3.2.Market size and forecast, by indication
7.2.2.3.3.Market size and forecast, by distribution channel
7.2.3.North America market size and forecast, type
7.2.4.North America market size and forecast, indication
7.2.5.North America market size and forecast, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe rapid acting insulin market, by country
7.3.2.1.Germany
7.3.2.1.1.Market size and forecast, by type
7.3.2.1.2.Market size and forecast, by indication
7.3.2.1.3.Market size and forecast, by distribution channel
7.3.2.2.UK
7.3.2.2.1.Market size and forecast, by type
7.3.2.2.2.Market size and forecast, by indication
7.3.2.2.3.Market size and forecast, by distribution channel
7.3.2.3.France
7.3.2.3.1.Market size and forecast, by type
7.3.2.3.2.Market size and forecast, by indication
7.3.2.3.3.Market size and forecast, by distribution channel
7.3.2.4.Italy
7.3.2.4.1.Market size and forecast, by type
7.3.2.4.2.Market size and forecast, by indication
7.3.2.4.3.Market size and forecast, by distribution channel
7.3.2.5.Spain
7.3.2.5.1.Market size and forecast, by type
7.3.2.5.2.Market size and forecast, by indication
7.3.2.5.3.Market size and forecast, by distribution channel
7.3.2.6.Rest of Europe
7.3.2.6.1.Market size and forecast, by type
7.3.2.6.2.Market size and forecast, by indication
7.3.2.6.3.Market size and forecast, by distribution channel
7.3.3.Europe market size and forecast, type
7.3.4.Europe market size and forecast, indication
7.3.5.Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific Rapid acting insulin market, by country
7.4.2.1.China
7.4.2.1.1.Market size and forecast, by type
7.4.2.1.2.Market size and forecast, by indication
7.4.2.1.3.Market size and forecast, by distribution channel
7.4.2.2.Japan
7.4.2.2.1.Market size and forecast, by type
7.4.2.2.2.Market size and forecast, by indication
7.4.2.2.3.Market size and forecast, by distribution channel
7.4.2.3.Australia
7.4.2.3.1.Market size and forecast, by type
7.4.2.3.2.Market size and forecast, by indication
7.4.2.3.3.Market size and forecast, by distribution channel
7.4.2.4.India
7.4.2.4.1.Market size and forecast, by type
7.4.2.4.2.Market size and forecast, by indication
7.4.2.4.3.Market size and forecast, by distribution channel
7.4.2.5.Rest of Asia-Pacific
7.4.2.5.1.Market size and forecast, by type
7.4.2.5.2.Market size and forecast, by indication
7.4.2.5.3.Market size and forecast, by distribution channel
7.4.3.Asia-Pacific market size and forecast, by type
7.4.4.Asia-Pacific market size and forecast, by indication
7.4.5.Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA rapid acting insulin market, by country
7.5.2.1.Latin America
7.5.2.1.1.Market size and forecast, by type
7.5.2.1.2.Market size and forecast, by indication
7.5.2.1.3.Market size and forecast, by distribution channel
7.5.2.2.Middle East & Africa
7.5.2.2.1.Market size and forecast, by type
7.5.2.2.2.Market size and forecast, by indication
7.5.2.2.3.Market size and forecast, by distribution channel
7.5.3.LAMEA market size and forecast, by type
7.5.4.LAMEA market size and forecast, by indication
7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES
8.1.ADOCIA SAS
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.Biocon Limited
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segment
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.Eli Lilly And Company
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segment
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Gan & Lee Pharmaceuticals
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments
8.5.Geropharm LLC
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments
8.6.Mannkind Corporation
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segment
8.6.4.Product portfolio
8.6.5.Business performance
8.7.Novo Nordisk A/S
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segment
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Sanofi S.A.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segment
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Wockhadt Ltd.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segment
8.9.4.Product portfolio
8.9.5.Business performance

List of Tables

TABLE 01.RAPID ACTING INSULIN MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
TABLE 02.RAPID ACTING INSULIN MARKET FOR LISPRO INSULIN, BY REGION, 2019-2027 ($MILLION)
TABLE 03.RAPID ACTING INSULIN MARKET FOR ASPART INSULIN, BY REGION, 2019-2027 ($MILLION)
TABLE 04.RAPID ACTING INSULIN MARKET FOR GLULISINE INSULIN, BY REGION, 2019-2027 ($MILLION)
TABLE 05.RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 06.RAPID ACTING INSULIN MARKET FOR TYPE 1 DIABETES, BY REGION, 2019-2027 ($MILLION)
TABLE 07.RAPID ACTING INSULIN MARKET FOR TYPE 2 DIABETES, BY REGION, 2019-2027 ($MILLION)
TABLE 08.RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 09.RAPID ACTING INSULIN MARKET FOR HOSPITAL PHARMACY, BY REGION, 2019-2027 ($MILLION)
TABLE 10.RAPID ACTING INSULIN MARKET FOR DRUG STORE & RETAIL PHARMACY, BY REGION, 2019-2027 ($MILLION)
TABLE 11.RAPID ACTING INSULIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2019-2027 ($MILLION)
TABLE 12.RAPID ACTING INSULIN MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 13.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 14.U.S. RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 15.U.S. RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 16.U.S. RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 17.CANADA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 18.CANADA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 19.CANADA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 20.MEXICO RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 21.MEXICO RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 22.MEXICO RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 23.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 24.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 25.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 26.EUROPE RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 27.GERMANY RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 28.GERMANY RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 29.GERMANY RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 30.UK RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 31.UK RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 32.UK RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 33.FRANCE RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 34.FRANCE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 35.FRANCE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 36.ITALY RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 37.ITALY RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 38.ITALY RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 39.SPAIN RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 40.SPAIN RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 41.SPAIN RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 42.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 43.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 44.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 45.EUROPE RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 46.EUROPE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 47.EUROPE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 48.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 49.CHINA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 50.CHINA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 51.CHINA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 52.JAPAN RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 53.JAPAN RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 54.JAPAN RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 55.AUSTRALIA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 56.AUSTRALIA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 57.AUSTRALIA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 58.INDIA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 59.INDIA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 60.INDIA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 61.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 62.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 63.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 64.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 65.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 66.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY DISTRIBUTION MARKET, 2019-2027 ($MILLION)
TABLE 67.LAMEA RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 68.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 69.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 70.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 71.MIDDLE EAST & AFRICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 72.MIDDLE EAST & AFRICARAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 73.MIDDLE EAST & AFRICARAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 74.LAMEA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 75.LAMEA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 76.LAMEA RAPID ACTING INSULIN MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 01.ADOCIA: COMPANY SNAPSHOT
TABLE 02.ADOCIA: OPERATING SEGMENTS
TABLE 03.ADOCIA: PRODUCT PORTFOLIO
TABLE 04.BIOCON: COMPANY SNAPSHOT
TABLE 05.BIOCON: OPERATING SEGMENTS
TABLE 06.BIOCON: PRODUCT PORTFOLIO
TABLE 07.ELI LILLY: COMPANY SNAPSHOT
TABLE 08.ELI LILLY: OPERATING SEGMENTS
TABLE 09.ELI LILLY: PRODUCT PORTFOLIO
TABLE 10.GAN&LEE: COMPANY SNAPSHOT
TABLE 11.GAN&LEE: PRODUCT PORTFOLIO
TABLE 12.GEROPHARM: COMPANY SNAPSHOT
TABLE 13.GEROPHARM: OPERATING SEGMENTS
TABLE 14.GEROPHARM: PRODUCT PORTFOLIO
TABLE 15.MANNKIND: COMPANY SNAPSHOT
TABLE 16.MANNKIND: OPERATING SEGMENTS
TABLE 17.MANNKIND: PRODUCT PORTFOLIO
TABLE 18.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 19.NOVO NORDISK: OPERATING SEGMENTS
TABLE 20.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 21.SANOFI: COMPANY SNAPSHOT
TABLE 22.SANOFI: PRODUCT PORTFOLIO
TABLE 23.WOCKHARDT: COMPANY SNAPSHOT
TABLE 24.WOCKHARDT: OPERATING SEGMENTS
TABLE 25.WOCKHARDT: PRODUCT PORTFOLIO

List of Figures

FIGURE 01.GLOBAL RAPID ACTING INSULIN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2018-2021
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.MODERATE BARGANING POWER OF BUYERS
FIGURE 08.MODERATE BARGANING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.HIGH COMPETITIVE RIVALRY
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR LISPRO INSULIN BY COUNTRY, 2019-2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR ASPART INSULIN BY COUNTRY, 2019-2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR GLULISINE INSULIN BY COUNTRY, 2019-2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR TYPE 1 DIABETES BY COUNTRY, 2019-2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR TYPE 2 DIABETES BY COUNTRY, 2019-2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR HOSPITAL PHARMACY BY COUNTRY, 2019-2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR DRUG STORE & RETAIL PHARMACY BY COUNTRY, 2019-2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR ONLINE PROVIDERS BY COUNTRY, 2019-2027 (%)
FIGURE 21.U.S. RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 22.CANADA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 23.MEXICO RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 24.GERMANY RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 25.UK RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 26.FRANCE RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 27.ITALY RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 28.SPAIN RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 29.REST OF EUROPE RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 30.CHINA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 31.JAPAN RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 32.AUSTRALIA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 33.INDIA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 34.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 35.LATIN AMERICA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 36.MIDDLE EAST & AFRICA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
FIGURE 01.ADOCIA: REVENUE, 2017-2019 ($MILLION)
FIGURE 02.BIOCON: REVENUE, 2018-2020 ($MILLION)
FIGURE 03.BIOCON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 04.BIOCON: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 05.ELI LILLY: REVENUE, 2018-2019 ($MILLION)
FIGURE 06.ELI LILLY: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 07.ELI LILLY: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 08.MANNKIND: REVENUE, 2019-2020 ($MILLION)
FIGURE 09.NOVO NORDISK: REVENUE, 2018-2020 ($MILLION)
FIGURE 10.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 11.NOVO NORDISK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 12.SANOFI: REVENUE, 2017-2019 ($MILLION)
FIGURE 13.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 14.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 15.WOCKHARDT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 16.WOCKHARDT: REVENUE SHARE BY REGION, 2019 (%)

Companies Mentioned
Some of the key players operating in the rapid acting insulin market include ADOCIA SAS, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Geropharm LLC, Mannkind Corporation, Novo Nordisk A/S, Sanofi S.A., and Wockhadt Ltd.